VCNX - Vaccinex, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.9300
-0.5700 (-10.36%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.5000
Open5.3900
Bid0.39 x 3000
Ask6.54 x 1400
Day's Range4.9300 - 5.3900
52 Week Range3.3200 - 12.0000
Volume9,724
Avg. Volume4,309
Market Cap56.575M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-9.36
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.33
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Vaccinex, Inc. Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503 (Pepinemab) in Huntington’s Disease (the “SIGNAL Trial”) at Cambridge Healthtech Institute’s 18th Annual PepTalk

    ROCHESTER, N.Y., Jan. 17, 2019 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to.

  • GlobeNewswire5 days ago

    Vaccinex, Inc. Announces Completion of Enrollment for Its “SIGNAL” Huntington’s Disease Trial

    ROCHESTER, N.Y., Jan. 16, 2019 -- Vaccinex, Inc. (Nasdaq: VCNX) announced today that it has completed subject enrollment for the SIGNAL trial.  SIGNAL is a Phase 2,.

  • Simply Wall St.last month

    Do Insiders Own Lots Of Shares In Vaccinex, Inc. (NASDAQ:VCNX)?

    A look at the shareholders of Vaccinex, Inc. (NASDAQ:VCNX) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning Read More...

  • GlobeNewswirelast month

    Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research

    ROCHESTER, N.Y., Dec. 12, 2018 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to.

  • ACCESSWIRE2 months ago

    Vaccinex, Inc. to Present at the 11th Annual LD Micro Main Event

    LOS ANGELES, CA / ACCESSWIRE / November 27, 2018 / Vaccinex, Inc. (NASDAQ: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious ...

  • GlobeNewswire2 months ago

    Vaccinex, Inc. Gives Podium Presentation and Poster at the Society for Immunotherapy of Cancer Annual Meeting

    Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announces details of a presentation and poster on November 9th and 10th at the Annual Conference of the Society of Immunotherapy for Cancer in Washington, D.C., held from November 7-11. Both the presentation, which was given by Gregory B. Lesinsky, M.D., Ph.D. from the Winship Cancer Institute of Emory University, and the multi-author poster outlined the action of VX15 (pepinemab) anti-semaphorin 4D antibody as reducing immune suppression of myeloid-derived cells thereby restoring the ability of dendritic cells and cytotoxic T cells to migrate into the tumor.  In addition, it is believed that VX15 (pepinemab) enhances the activity of co-administered immunotherapies, as was shown in preclinical colon, head and neck and melanoma mouse models.  For example, the anti-semaphorin 4D compound on which VX15 (pepinemab) is based, when combined with anti-CTLA resulted in a 90 percent complete tumor rejection (p

  • GlobeNewswire2 months ago

    Vaccinex Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today disclosed its financial results for the third quarter and nine months ended September 30, 2018, and provided a corporate update. During the quarter, Vaccinex presented preliminary data on its anti-semaphorin 4D monoclonal antibody technology at the fourth International Cancer Immunotherapy Conference.

  • GlobeNewswire2 months ago

    Vaccinex, Inc. Presents Overview of the Clinical Development of VX15 (pepinemab) for the Potential Treatment of Huntington’s Disease at the Huntington Study Group’s 2018 Annual Meeting

    Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announces details of a presentation and poster on November 8th and 9th at the Huntington Study Group’s 25th Annual Meeting: HSG 2018 in Houston, Tex. Both the presentation and the poster outlined the action of VX15 (pepinemab) anti-semaphorin 4D antibody as ameliorating the neurodegenerative processes in preclinical and clinical studies.  The company has completed and analyzed data from Cohort A the SIGNAL trial, and expects to complete enrollment in Cohort B, a randomized, double-blind, placebo-controlled phase 2 study of VX15 (pepinemab) in approximately 260 patients with Huntington’s Disease.  Endpoints include quantitative cognitive and motor assessments and functional and patient-reported outcomes, as well as imaging measures of change in energy metabolism and volumetric MRI in defined brain regions.

  • GlobeNewswire2 months ago

    Vaccinex, Inc. to Present Data on Its Semaphorin 4D Monoclonal Antibody Programs at Two Conferences Focused on Cancer Immunotherapy and Huntington’s Disease

    The abstract, “Clinical Developments of VX15 Anti-Semaphorin 4D Antibody as a Potential Treatment for Huntington’s Disease,” will be presented as a poster on November 8th at the Huntington Study Group’s 25th Annual Meeting, HSG 2018.  The following day, the abstract will be presented in an oral session.  The conference will be held from November 8-10, 2018 in Houston, Tex. Subsequently, the abstract, “Reprogramming Suppressive Myeloid Cells in Tumor Microenvironment with Pepinemab, First-in-Class Semaphorin 4D MAb, Enhances Combination Immunotherapy,” will be presented in a poster at the 33rd Annual Meeting of the Society of Immunotherapy of Cancer on November 9th and 10th.

  • Why Did Vaccinex Inc’s’ (NASDAQ:VCNX) Insiders Buy Up More Shares?
    Simply Wall St.4 months ago

    Why Did Vaccinex Inc’s’ (NASDAQ:VCNX) Insiders Buy Up More Shares?

    Vaccinex, Inc. operates as a clinical-stage biotechnology company. Vaccinex’s insiders have invested more than 2.46 million shares in the small-cap stocks within the past three months. Generally, insiders buying moreRead More...

  • Benzinga5 months ago

    Oppenheimer: Vaccinex Has Catalysts In Novel Therapies For Challenging Diseases

    Vaccinex Inc (NASDAQ: VCNX ) has fallen nearly 17 percent since its Aug. 8 Nasdaq  debut , but one analyst anticipates relief from the growing pains. The Analyst Oppenheimer analyst Leland Gershell initiated ...

  • Benzinga6 months ago

    The IPO Outlook For The Week: An Airline, A Biotech And 2 Banks

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Amalgamated Bank (AMAL) will issue 6.7 million shares between $15 and $17 Thursday on the Nasdaq. The 95-year-old financial ...